Patricia M. Danzon : Citation Profile

University of Pennsylvania

18

H index

27

i10 index

1322

Citations

RESEARCH PRODUCTION:

43

Articles

17

Papers

3

Books

6

Chapters

EDITOR:

1

Books edited

RESEARCH ACTIVITY:

   36 years (1982 - 2018). See details.
   Cites by year: 36
   Journals where Patricia M. Danzon has often published
   Relations with other researchers
   Recent citing documents: 37.    Total self citations: 20 (1.49 %)

MORE DETAILS IN:
ABOUT THIS REPORT:

   Permalink: http://citec.repec.org/pda291
   Updated: 2025-12-13    RAS profile: 2024-04-05    
   Missing citations? Add them    Incorrect content? Let us know

Relations with other researchers

Works with:

Authors registered in RePEc who have co-authored more than one work in the last five years with Patricia M. Danzon.

Is cited by:

Brekke, Kurt (30)

Straume, Odd Rune (21)

Jelovac, Izabela (21)

Pammolli, Fabio (19)

Dubois, Pierre (19)

Kyle, Margaret (18)

Pertile, Paolo (13)

Magazzini, Laura (13)

Grembi, Veronica (13)

Jimenez-Martin, Sergi (13)

LEVAGGI, ROSELLA (12)

Cites to:

Valletti, Tommaso (8)

Cockburn, Iain (8)

Szymanski, Stefan (8)

Kyle, Margaret (6)

DiMasi, Joseph (6)

Jack, William (6)

Dranove, David (6)

Henderson, Rebecca (5)

Philipson, Tomas (5)

Maskus, Keith (4)

Ganslandt, Mattias (4)

Main data

Where Patricia M. Danzon has published?

Journals with more than one article published# docs
Journal of Law and Economics5
Journal of Health Economics5
Health Economics5
Journal of Policy Analysis and Management4
International Journal of the Economics of Business3
The Journal of Business2
Managerial and Decision Economics2
The Journal of Legal Studies2
American Economic Review2

Working Papers Series with more than one paper published# docs
NBER Working Papers / National Bureau of Economic Research, Inc10
Monograph / Office of Health Economics3
Working Papers / The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State2

Recent works citing Patricia M. Danzon (2025 and 2024)

YearTitle of citing document
2024Optimal Liability Rules for Combined Human-AI Health Care Decisions. (2024). Musy, Olivier ; CHOPARD, Bertrand. In: Working Papers AFED. RePEc:afd:wpaper:2404.

Full description at Econpapers || Download paper

2025The Impact of Acquisitions in the Biotechnology Sector on R&D Productivity. (2024). Verginer, Luca ; Riccaboni, Massimo ; van Lidth, Jeroen ; Parisi, Federica. In: Papers. RePEc:arx:papers:2203.12968.

Full description at Econpapers || Download paper

2024Interstate migration‐based social networks and M&A decisions. (2024). Lee, Suin ; Park, Jung Chul ; Pantzalis, Christos. In: The Financial Review. RePEc:bla:finrev:v:59:y:2024:i:1:p:113-153.

Full description at Econpapers || Download paper

2024How does medical insurance contribution affect corporate value? Evidence from China. (2024). Wang, Jiyuan ; Lu, Jiankun ; Li, Xuchao. In: Journal of Risk & Insurance. RePEc:bla:jrinsu:v:91:y:2024:i:1:p:57-92.

Full description at Econpapers || Download paper

2025Legislation, Regulation and Litigation: Demand for U.S. Legal Services in Historical Perspective. (2025). Slattery, Cailin ; Reshef, Ariell. In: CESifo Working Paper Series. RePEc:ces:ceswps:_11661.

Full description at Econpapers || Download paper

2024Acquiring R&D Projects: Who, When, and What? Evidence from Antidiabetic Drug Development. (2024). Seldeslachts, Jo ; veugelers, reinhilde ; Newham, Melissa ; Malek, Jan. In: Discussion Papers of DIW Berlin. RePEc:diw:diwwpp:dp2073.

Full description at Econpapers || Download paper

2024Seeking efficiency or price gouging? Evidence from pharmaceutical mergers. (2024). Hammoudeh, Mosab ; Nain, Amrita. In: Journal of Corporate Finance. RePEc:eee:corfin:v:87:y:2024:i:c:s0929119924000853.

Full description at Econpapers || Download paper

2024Health policy, price regulation, and innovation: Evidence from China’s vaccine industry. (2024). Geng, Hao ; Shi, Ce Matthew. In: Journal of Development Economics. RePEc:eee:deveco:v:167:y:2024:i:c:s0304387823001852.

Full description at Econpapers || Download paper

2024The impact of changing the reference countries on the list prices for patented medicines in Canada: A policy analysis. (2024). Hollis, Aidan ; Zhang, Wei ; Grootendorst, Paul ; Guh, Daphne P ; Anis, Aslam H. In: Health Policy. RePEc:eee:hepoli:v:144:y:2024:i:c:s0168851024000745.

Full description at Econpapers || Download paper

2025Price regulation and competition among on-patent anticancer drugs in Italy. (2025). Mancusi, Maria ; Vassallo, Chiara ; Fiorentino, Francesca ; di Costanzo, Alessandra ; Candelora, Laura ; Caimmi, Michele ; Canali, Beatrice. In: Health Policy. RePEc:eee:hepoli:v:157:y:2025:i:c:s0168851025001046.

Full description at Econpapers || Download paper

2024The evolution of the ability to effectively innovate in a transnational organization – A configurational analysis. (2024). Macro, Samantha ; Ott, Ursula F. In: Journal of International Management. RePEc:eee:intman:v:30:y:2024:i:6:s1075425324000814.

Full description at Econpapers || Download paper

2024Market discipline and policy loans. (2024). Niehaus, Greg ; Chiang, Chia-Chun. In: Journal of Banking & Finance. RePEc:eee:jbfina:v:159:y:2024:i:c:s0378426623002716.

Full description at Econpapers || Download paper

2024The interplay between product development failures and alliance portfolio properties in the formation of exploration versus exploitation alliances. (2024). Ozmel, Umit ; Bae, Joonhyung. In: Journal of Business Research. RePEc:eee:jbrese:v:177:y:2024:i:c:s0148296324001267.

Full description at Econpapers || Download paper

2025Mutual scrutiny and information exchange: Uncovering R&D Partners’ impact on ESG performance in the biopharmaceutical industry. (2025). Zheng, Qinqin ; Hu, Yahan. In: Journal of Business Research. RePEc:eee:jbrese:v:195:y:2025:i:c:s0148296325002310.

Full description at Econpapers || Download paper

2025Time to say goodbye? The role of SBIR funding, VC rounds, and initial alliance for director exit in new ventures. (2025). van den Oever, Koen ; Chila, Vilma. In: Journal of Business Venturing. RePEc:eee:jbvent:v:40:y:2025:i:3:s0883902625000102.

Full description at Econpapers || Download paper

2025Taking the competitor’s pill: When combination therapies enter pharmaceutical markets. (2025). Straume, Odd Rune ; Dalen, Dag Morten ; Brekke, Kurt R. In: Journal of Health Economics. RePEc:eee:jhecon:v:101:y:2025:i:c:s0167629625000104.

Full description at Econpapers || Download paper

2025Procurement institutions and essential drug supply in low and middle-income countries. (2025). Zahur, Nahim Bin ; Wang, Lucy Xiaolu. In: Journal of Health Economics. RePEc:eee:jhecon:v:101:y:2025:i:c:s016762962500030x.

Full description at Econpapers || Download paper

2025When the drugs (don’t) work: The role of science in product commercialization. (2025). Anckaert, Paul-Emmanuel. In: Research Policy. RePEc:eee:respol:v:54:y:2025:i:5:s0048733325000666.

Full description at Econpapers || Download paper

2024Internal versus external capital markets and risk-taking. (2024). Shiu, Yung-Ming ; Hsiao, Ching-Yuan. In: International Review of Economics & Finance. RePEc:eee:reveco:v:92:y:2024:i:c:p:503-519.

Full description at Econpapers || Download paper

2024How does market competition affect enterprise cooperative innovation? The moderating role of intellectual property protection and government subsidies. (2024). Zhang, Danni ; Cheng, LI ; Yu, Yiyong. In: Technovation. RePEc:eee:techno:v:137:y:2024:i:c:s0166497224001524.

Full description at Econpapers || Download paper

2025Milestone payments in alliances: The moderating effect of equity ownership and network centrality. (2025). Wu, Sibin ; Su, Taoyong ; Levitas, Edward ; Hou, Wanrong. In: Technovation. RePEc:eee:techno:v:142:y:2025:i:c:s0166497225000240.

Full description at Econpapers || Download paper

2025The Long-Run Impact of Changes in Prescription Drug Sales on Mortality and Hospital Utilization in Belgium, 1998–2019. (2025). Lichtenberg, Frank R. In: Econometrics. RePEc:gam:jecnmx:v:13:y:2025:i:3:p:25-:d:1685509.

Full description at Econpapers || Download paper

2024Individuals social concern, externalities and voluntary vaccination: Monopoly and first-best public policy. (2024). Kundu, Sumana ; Pal, Rupayan. In: Indira Gandhi Institute of Development Research, Mumbai Working Papers. RePEc:ind:igiwpp:2024-023.

Full description at Econpapers || Download paper

2025How do underwriting and investment activities affect P&C insurers’ capital adjustments? Evidence from Canada. (2025). Lai, Van Son ; Guidara, Alaa ; Zhao, Yang ; Yu, Min-Teh. In: Review of Quantitative Finance and Accounting. RePEc:kap:rqfnac:v:64:y:2025:i:2:d:10.1007_s11156-024-01314-z.

Full description at Econpapers || Download paper

2025Pre-entry experience, knowledge inheritance, and entrepreneurial resource mobilization. (2025). Martin, Xavier ; Chila, Vilma ; Devarakonda, Shivaram V. In: Small Business Economics. RePEc:kap:sbusec:v:65:y:2025:i:1:d:10.1007_s11187-025-01003-8.

Full description at Econpapers || Download paper

2024The impact of the Russia–Ukraine war on the world’s largest listed insurance firms. (2024). Gouveia, Ricardo ; Correia, Pedro ; Martins, Antonio Miguel. In: The Geneva Papers on Risk and Insurance - Issues and Practice. RePEc:pal:gpprii:v:49:y:2024:i:4:d:10.1057_s41288-023-00305-w.

Full description at Econpapers || Download paper

2025Acquisitions as catalysts for inventor departures in the biotechnology industry. (2025). Riccaboni, Massimo ; de Jeude, Jeroen Lidth ; Parisi, Federica ; Verginer, Luca. In: Palgrave Communications. RePEc:pal:palcom:v:12:y:2025:i:1:d:10.1057_s41599-025-04894-w.

Full description at Econpapers || Download paper

2024Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab. (2024). R W F van Leeuwen, ; R H J Mathijssen, ; Thielen, F W ; R J S D Heine, ; Uyl-De, C A ; Franken, M G. In: PLOS ONE. RePEc:plo:pone00:0293264.

Full description at Econpapers || Download paper

2024Explaining why increases in generic use outpace decreases in brand name medicine use in multisource markets and the role of regulation. (2024). Blankart, Katharina ; Vandoros, Sotiris. In: PLOS ONE. RePEc:plo:pone00:0301716.

Full description at Econpapers || Download paper

2024Passthrough of Retail Price Regulation in the Market for Pharmaceuticals. (2024). Markkanen, Jaakko. In: ETLA Working Papers. RePEc:rif:wpaper:123.

Full description at Econpapers || Download paper

2024The Effect of Branch Office Locations on Technical Efficiency: Evidence from the Indian Life Insurance Industry. (2024). Siddiqui, Shoaib Alam. In: Global Business Review. RePEc:sae:globus:v:25:y:2024:i:6:p:1559-1575.

Full description at Econpapers || Download paper

2024Insurance Development, Global Economic Policy Uncertainty and Geopolitical Risk: The Asymmetric Relationship Evidence from ASEAN-5. (2024). Soukchalern, Phongsili ; Kyophilavong, Phouphet ; Lim, Soyoung. In: Journal of Asian Economic Integration. RePEc:sae:jfasei:v:6:y:2024:i:2:p:154-168.

Full description at Econpapers || Download paper

2025Drug pricing models, no ‘one-size-fits-all’ approach: a systematic review and critical evaluation of pricing models in an evolving pharmaceutical landscape. (2025). Manders, Evert A ; den Berg, Sibren ; Visser, Saco J. In: The European Journal of Health Economics. RePEc:spr:eujhec:v:26:y:2025:i:4:d:10.1007_s10198-024-01731-w.

Full description at Econpapers || Download paper

2025International Corporate Development Activities and Information Disclosures in Earnings Calls. (2025). Ragozzino, Roberto ; Jiang, Guoliang Frank. In: Management International Review. RePEc:spr:manint:v:65:y:2025:i:2:d:10.1007_s11575-025-00574-8.

Full description at Econpapers || Download paper

2025Pharmaceutical Regulation and Incentives for Innovation in an International Perspective. (2025). Dubois, Pierre. In: TSE Working Papers. RePEc:tse:wpaper:131002.

Full description at Econpapers || Download paper

2024Harmonizing regulatory market approval of products with high safety requirements: Evidence from the European pharmaceutical market. (2024). Stargardt, Tom ; Grunwald, Fabian. In: Health Economics. RePEc:wly:hlthec:v:33:y:2024:i:7:p:1546-1564.

Full description at Econpapers || Download paper

2024To merge or not to merge? The impact of mergers and acquisitions on corporate success in the pharmaceutical industry. (2024). Stargardt, Tom ; Bssgen, Melanie. In: Managerial and Decision Economics. RePEc:wly:mgtdec:v:45:y:2024:i:4:p:2196-2209.

Full description at Econpapers || Download paper

Patricia M. Danzon has edited the books:

YearTitleTypeCited

Works by Patricia M. Danzon:

YearTitleTypeCited
1988The Political Economy of Workers Compensation: Lessons for Product Liability. In: American Economic Review.
[Full Text][Citation analysis]		article2
1990The Effects of Malpractice Litigation on Physicians Fees and Incomes. In: American Economic Review.
[Full Text][Citation analysis]		article7
1990The Effects of Malpractice Litigation on Physicians Fees and Incomes.(1990) In: Working Papers.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 7		paper
1991Liability for Medical Malpractice In: Journal of Economic Perspectives.
[Full Text][Citation analysis]		article82
2000Liability for medical malpractice.(2000) In: Handbook of Health Economics.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 82		chapter
1994Health Care Reform In: Australian Economic Review.
[Full Text][Citation analysis]		article8
2004Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands, and New Zealand In: Forum for Health Economics & Policy.
[Full Text][Citation analysis]		article63
2004Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands, and New Zealand.(2004) In: NBER Chapters.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 63		chapter
2003Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands and New Zealand.(2003) In: NBER Working Papers.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 63		paper
1994The Swedish patient compensation system: Myths and realities In: International Review of Law and Economics.
[Full Text][Citation analysis]		article3
2008Crises in medical malpractice insurance: Evidence of excessive price-cutting in the preceding soft market In: Journal of Banking & Finance.
[Full Text][Citation analysis]		article10
1997Price, Financial Quality, and Capital Flows in Insurance Markets In: Journal of Financial Intermediation.
[Full Text][Citation analysis]		article107
2000Cross-national price differences for pharmaceuticals: how large, and why? In: Journal of Health Economics.
[Full Text][Citation analysis]		article96
1982Hospital `profits : The effects of reimbursement policies In: Journal of Health Economics.
[Full Text][Citation analysis]		article16
2002Welfare effects of supplementary insurance: a comment In: Journal of Health Economics.
[Full Text][Citation analysis]		article10
2005Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances In: Journal of Health Economics.
[Full Text][Citation analysis]		article89
2003Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances.(2003) In: NBER Working Papers.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 89		paper
1985Liability and liability insurance for medical malpractice In: Journal of Health Economics.
[Full Text][Citation analysis]		article21
1984Separation of the redistributive and allocative functions of government : A public choice perspective In: Journal of Public Economics.
[Full Text][Citation analysis]		article5
2012Regulation of the Biopharmaceutical Industry In: Chapters.
[Full Text][Citation analysis]		chapter0
2012Effects of Regulation on Drug Launch and Pricing in Interdependent Markets In: Advances in Health Economics and Health Services Research.
[Full Text][Citation analysis]		chapter29
2008Effects of Regulation on Drug Launch and Pricing in Interdependent Markets.(2008) In: NBER Working Papers.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 29		paper
1990THE EFFECTS OF MALPRACTICE LITIGATION ON PHYSICIANS FEES AND INCOME. In: University of Chicago - George G. Stigler Center for Study of Economy and State.
[Citation analysis]		paper4
1990Mandated Employment-Based Health Insurance:Incidence and Efficiency Effects In: University of Chicago - George G. Stigler Center for Study of Economy and State.
[Citation analysis]		paper2
2002Pharmaceuticals: Access, Cost, Pricing, and Directions for the Future. 13th Annual Herbert Lourie Memorial Lecture on Health Policy In: Center for Policy Research Policy Briefs.
[Full Text][Citation analysis]		paper0
2002Pharmaceuticals: Access, Cost, Pricing, and Directions for the Future. 13th Annual Herbert Lourie Memorial Lecture on Health Policy In: Center for Policy Research Reports.
[Full Text][Citation analysis]		paper0
2007At what price? In: Nature.
[Full Text][Citation analysis]		article3
2014Regulation of the Pharmaceutical-Biotechnology Industry In: NBER Chapters.
[Full Text][Citation analysis]		chapter4
1999The Effects of Price Regulation on Productivity in Pharmaceuticals In: NBER Chapters.
[Full Text][Citation analysis]		chapter2
2004Mergers and Acquisitions in the Pharmaceutical and Biotech Industries In: NBER Working Papers.
[Full Text][Citation analysis]		paper82
2007Mergers and acquisitions in the pharmaceutical and biotech industries.(2007) In: Managerial and Decision Economics.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 82		article
2011Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement In: NBER Working Papers.
[Full Text][Citation analysis]		paper16
2015Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement.(2015) In: Health Economics.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 16		article
2011Vaccine Supply: Effects Of Regulation And Competition In: NBER Working Papers.
[Full Text][Citation analysis]		paper9
2011Vaccine Supply: Effects of Regulation and Competition.(2011) In: International Journal of the Economics of Business.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 9		article
2011Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets In: NBER Working Papers.
[Full Text][Citation analysis]		paper20
2012Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context In: NBER Working Papers.
[Full Text][Citation analysis]		paper18
2015Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context.(2015) In: Health Economics.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 18		article
2002Biotech-Pharmaceutical Alliances as a Signal of Asset and Firm Quality In: NBER Working Papers.
[Full Text][Citation analysis]		paper74
2003The Impact of Price Regulation on the Launch Delay of New Drugs - Evidence from Twenty-Five Major Markets in the 1990s In: NBER Working Papers.
[Full Text][Citation analysis]		paper100
2005The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s.(2005) In: Health Economics.
[Full Text][Citation analysis]
This paper has nother version. Agregated cites: 100		article
1997Trade and Price Differentials for Pharmaceuticals: Policy Options In: Monograph.
[Full Text][Citation analysis]		book5
2000Prices, Competition and Regulation in Pharmaceuticals: A Cross-National Comparison In: Monograph.
[Full Text][Citation analysis]		book4
2002The Life Cycle of Pharmaceuticals: A Cross-National Perspective In: Monograph.
[Full Text][Citation analysis]		book6
2011Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution? In: Occasional Paper.
[Full Text][Citation analysis]		paper2
1994Tort Reform: The Case of Medical Malpractice. In: Oxford Review of Economic Policy.
[Citation analysis]		article1
1990Alternative Liability Regimes for Medical Injuries In: The Geneva Papers on Risk and Insurance - Issues and Practice.
[Full Text][Citation analysis]		article4
1983Contingent Fees for Personal Injury Litigation In: Bell Journal of Economics.
[Full Text][Citation analysis]		article54
2018Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues In: PharmacoEconomics.
[Full Text][Citation analysis]		article14
2015Pharmacy Benefit Management: Are Reporting Requirements Pro- or Anticompetitive? In: International Journal of the Economics of Business.
[Full Text][Citation analysis]		article0
1997Price Discrimination for Pharmaceuticals: Welfare Effects in the US and the EU In: International Journal of the Economics of Business.
[Full Text][Citation analysis]		article34
1993The Economic Implications of Public Disability Insurance in the United States. In: Journal of Labor Economics.
[Full Text][Citation analysis]		article13
2002Health Insurance and the Growth in Pharmaceutical Expenditures In: Journal of Law and Economics.
[Full Text][Citation analysis]		article19
1984The Frequency and Severity of Medical Malpractice Claims. In: Journal of Law and Economics.
[Full Text][Citation analysis]		article36
1993Holdouts, Externalities, and the Single Owner: One More Salute to Ronald Coase: Comment. In: Journal of Law and Economics.
[Full Text][Citation analysis]		article0
2000Does Regulation Drive out Competition in Pharmaceutical Markets? In: Journal of Law and Economics.
[Full Text][Citation analysis]		article108
2001Workers Compensation Rate Regulation: How Price Controls Increase Costs. In: Journal of Law and Economics.
[Full Text][Citation analysis]		article11
1997Tort Liability: A Minefield for Managed Care? In: The Journal of Legal Studies.
[Full Text][Citation analysis]		article17
2001Comments on The Assault on Managed Care: Vicarious Liability, ERISA Preemption, and Class Actions. In: The Journal of Legal Studies.
[Full Text][Citation analysis]		article0
1994Price Cutting in Liability Insurance Markets. In: The Journal of Business.
[Full Text][Citation analysis]		article30
2000Rate Regulation, Safety Incentives, and Loss Growth in Workers Compensation Insurance. In: The Journal of Business.
[Full Text][Citation analysis]		article6
2002A general model of the impact of absenteeism on employers and employees In: Health Economics.
[Full Text][Citation analysis]		article44
1999Medical negligence and the NHS: an economic analysis In: Health Economics.
[Full Text][Citation analysis]		article8
1995A measure of malpractice: Medical injury, malpractice litigation and patient compensation, by Paul C. Weiler et al. Cambridge, MA: Harvard University Press, 1993, 178 pp., $29.95 cloth In: Journal of Policy Analysis and Management.
[Full Text][Citation analysis]		article0
1982Regulation and its reform, by Stephen Breyer. Cambridge, MA: Harvard University Press, 1982, 472 pp. Price: $25.00 In: Journal of Policy Analysis and Management.
[Full Text][Citation analysis]		article0
1983Regulatory policy and practices: Regulating better and regulating less, by Fred Thomson and L.R. Jones. New York: Praeger Publishers, 1982, 253 pp. Price: $29.95 In: Journal of Policy Analysis and Management.
[Full Text][Citation analysis]		article0
1983Risk by choice: Regulating health and safety in the workplace, by W. Kip Viscusi. Cambridge, MA: Harvard University Press, 1983, 200 pp. Price: $18.50 In: Journal of Policy Analysis and Management.
[Full Text][Citation analysis]		article1
2007Dynamic competition in pharmaceuticals: cross-national evidence from new drug diffusion In: Managerial and Decision Economics.
[Full Text][Citation analysis]		article6
1990Mandated Employment-Based Health Insurance: Incidence and Efficiency Effects In: Working Papers.
[Full Text][Citation analysis]		paper0

CitEc is a RePEc service, providing citation data for Economics since 2001. Last updated November, 20 2025. Contact: CitEc Team